Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone781-995-2443
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees62
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Replimune Group (NASDAQ:REPL) Frequently Asked Questions
What is Replimune Group's stock symbol?
Replimune Group trades on the NASDAQ under the ticker symbol "REPL."
How were Replimune Group's earnings last quarter?
Replimune Group Inc (NASDAQ:REPL) issued its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.02. View Replimune Group's Earnings History.
When is Replimune Group's next earnings date?
What price target have analysts set for REPL?
4 brokers have issued 12-month target prices for Replimune Group's stock. Their predictions range from $24.00 to $28.00. On average, they anticipate Replimune Group's share price to reach $26.00 in the next year. This suggests a possible upside of 133.6% from the stock's current price. View Analyst Price Targets for Replimune Group.
What is the consensus analysts' recommendation for Replimune Group?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Replimune Group.
What are Wall Street analysts saying about Replimune Group stock?
Here are some recent quotes from research analysts about Replimune Group stock:
- 1. Chardan Capital analysts commented, "We expect the 4Q19 data from the phase I portion, potentially at the Cancer (SITC) annual meeting in November, will focus on safety and early signals of immune activity of RP1 as a single agent and in the combo setting. Per management, the company plans to accumulate data from the phase II cohorts over the next ~6 months and begin reporting on a per cohort basis over 2020 (consistent with prior timelines). RP1 trial, a registration-directed randomized controlled study in cutaneous squamous cell carcinoma (CSCC) +/- Regeneron’s (unrated) anti-PD1 cemiplimab is expected to begin in August. Replimune ended the quarter with $120.8 mm in cash, cash equivalents and short-term investments. This provides the company with a cash runway into calendar year 2H21." (8/15/2019)
- 2. According to Zacks Investment Research, "Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. " (7/3/2019)
Has Replimune Group been receiving favorable news coverage?
Media coverage about REPL stock has been trending negative recently, InfoTrie reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Replimune Group earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Replimune Group.
Are investors shorting Replimune Group?
Replimune Group saw a decrease in short interest in July. As of July 15th, there was short interest totalling 600,000 shares, a decrease of 62.8% from the June 15th total of 1,614,000 shares. Based on an average trading volume of 40,900 shares, the days-to-cover ratio is currently 14.7 days. Approximately 7.5% of the shares of the stock are sold short. View Replimune Group's Current Options Chain.
Who are some of Replimune Group's key competitors?
Some companies that are related to Replimune Group include Regenxbio (RGNX), Coherus Biosciences (CHRS), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Orchard Therapeutics (ORTX), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), Alector (ALEC), NanoString Technologies (NSTG), Twist Bioscience (TWST), Rubius Therapeutics (RUBY), BAVARIAN NORDIC/S (BVNRY), Adverum Biotechnologies (ADVM) and Cortexyme (CRTX).
What other stocks do shareholders of Replimune Group own?
Who are Replimune Group's key executives?
Replimune Group's management team includes the folowing people:
- Mr. Philip Astley-Sparke, Exec. Chairman, Sec. & Treasurer (Age 48)
- Dr. Robert Coffin, Pres, CEO & Director (Age 54)
- Dr. Colin Love, Chief Operating Officer (Age 61)
- Dr. Pamela Esposito, Chief Bus. Officer (Age 45)
- Stephen Gorgol, Chief Accounting Officer
When did Replimune Group IPO?
(REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.
Who are Replimune Group's major shareholders?
Replimune Group's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.21%), Foresite Capital Management III LLC (2.46%), Emerald Mutual Fund Advisers Trust (2.25%), Emerald Advisers LLC (2.19%), Vanguard Group Inc. (1.69%) and Citadel Advisors LLC (0.59%). Company insiders that own Replimune Group stock include Fund Iv Gp LP Omega and Joseph P Slattery. View Institutional Ownership Trends for Replimune Group.
Which institutional investors are selling Replimune Group stock?
Which institutional investors are buying Replimune Group stock?
REPL stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Foresite Capital Management III LLC, Morgan Stanley, Wells Fargo & Company MN, Citadel Advisors LLC, Emerald Mutual Fund Advisers Trust and Northern Trust Corp. Company insiders that have bought Replimune Group stock in the last two years include Fund Iv Gp LP Omega and Joseph P Slattery. View Insider Buying and Selling for Replimune Group.
How do I buy shares of Replimune Group?
Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Replimune Group's stock price today?
One share of REPL stock can currently be purchased for approximately $11.13.
How big of a company is Replimune Group?
Replimune Group has a market capitalization of $352.49 million. The company earns $-30,830,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Replimune Group employs 62 workers across the globe.View Additional Information About Replimune Group.
What is Replimune Group's official website?
How can I contact Replimune Group?
Replimune Group's mailing address is 18 COMMERCE WAY, WOBURN MA, 01801. The company can be reached via phone at 781-995-2443 or via email at [email protected]
MarketBeat Community Rating for Replimune Group (NASDAQ REPL)
MarketBeat's community ratings are surveys of what our community members think about Replimune Group and other stocks. Vote "Outperform" if you believe REPL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPL will underperform the S&P 500 over the long term. You may vote once every thirty days.
